Novartis AG (NVS) annual results, year to 31 December 2022: revenue USD 42,206 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2022 it reported revenue from the sale of goods of USD 42,206 million, down 1.3% on the year before. Its profit attributable to shareholders was USD 6,955 million, down 71.0%, and diluted earnings per share USD 3.17.
The year to 31 December 2022, against the year before
| Year to | Dec 2021 † | Dec 2022 † |
|---|---|---|
| Revenue from the sale of goods | 42,781 | 42,206 |
| Cost of sales | 11,735 | 11,582 |
| Gross profit | 32,239 | 31,879 |
| Research and development | 8,641 | 9,172 |
| Selling, general and administrative | 12,827 | 12,193 |
| Operating profit | 10,056 | 7,946 |
| Profit before tax | 24,530 | 7,177 |
| Income tax | 1,625 | 1,128 |
| Profit for the year | 24,018 | 6,955 |
| Profit attributable to shareholders | 24,021 | 6,955 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2021 † | Dec 2022 † |
|---|---|---|
| Cash from operations | 15,071 | 14,236 |
| Purchase of property, plant and equipment | 1,066 | 916 |
| Free cash flow | 14,005 | 13,320 |
| Dividends paid | 7,368 | 7,506 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2021 † | Dec 2022 † |
|---|---|---|
| Total assets | 131,795 | 117,453 |
| Equity attributable to shareholders | 67,655 | 59,342 |
| Cash and cash equivalents | 12,407 | 7,517 |
| Borrowings, as filed | 25,523 | 22,485 |
| Lease liabilities | 1,896 | 1,789 |
| Inventories | 6,666 | 7,175 |
| Goodwill | 29,595 | 29,301 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2021 † | Dec 2022 † |
|---|---|---|
| Return on year-end equity | 35.5% | 11.7% |
| Effective tax rate | 6.6% | 15.7% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022, this page
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
Source
20-F for the year to 31 December 2022, filed 31 January 2025, accession 0001370368-25-000004: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.